This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Dewey A. Nelson, MD
48 Omega Dr Newark, DE 19713

Arch Neurol. 1991;48(10):1012-1013.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—Controversy concerning the intraspinal use of methylprednisolone acetate (Depo-Medrol, Upjohn Co, Kalamazoo, Mich) began in 1970, naturally leading to a number of editors' invitations (as here) for me to reply to adverse opinions.

The manufacturer issued its first warning concerning epidural use in the United States in October 1989 and in Australia in November 1990. Because the drug has a 36-month shelf life, Strong et al may not have yet seen the new package-insert pamphlet, and the Upjohn Company plans no general "Dear Doctor" letter. Six months after the warning against epidural use in the United States was first printed, I was notified that about 150 patients in Western Australia claimed complications from epidural steroid therapy.¹ Why such a large number of patients in one Australian state spontaneously reported their symptoms without media induction or medical publications is unknown. Contrary to Strong et al, I believe . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?